ACKNOWLEDGMENT: “This project has received funding from the European Union’s H2020-MSCA-RISE-2015 under grant agreement No 691247”.

Beneficiary 9 - IASIS Pharmaceuticals Hellas S.A (Iasis)

General Description: IASIS Pharmaceuticals Hellas S.A. with the distinctive title IΑSIS PHARMA, is a purely Greek pharmaceutical industry activated in production, research and development, import, export and trade of pharmaceutical products and cosmetics. IASIS PHARMA’s manufacturing unit is located in Kamatero district in Attica. It complies with the most strict and up-to-date patterns of production (cGMP, cGLP) and it has also been certified by Bureau Veritas with ISO 9001:2008. The unit has been authorized by the National Organization for Medicines (EOF) and has also been inspected by other countries’ National Organizations for Medicines (NOM). The Research and Development constitutes a strategic target of IASIS PHARMA. Basic activity is the development of medicines and, in general, of all pharmaceutical kinds through as much in innovative finished formulations as through new routes of administration.  IASIS PHARMA in order to maintain its outstanding standards systematically invests in scientific human potential and upgrades the technological equipment and building infrastructure too.